Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
Date:11/25/2008

MONTREAL, Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, on December 9, 2008.

The presentation is entitled "Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML". The trial was an open label, multi-center study evaluating the safety and efficacy of AEG35156 in combination with chemotherapy in AML patients in first relapse after a short initial CR or with primary refractory disease. A total of 51 patients were enrolled in the study. The results demonstrate that AEG35156 is well tolerated at 350 mg/m2 in combination with idarubicin and cytarabine. The results also support the finding that AEG35156 combination therapy may induce high response rates in AML patients not responding to frontline induction therapy. Updated results on additional patients will be presented at the ASH Annual Meeting.

The study's principal investigator, Dr. Aaron D. Schimmer, M.D., Ph.D. of the Princess Margaret Hospital in Toronto will present the results of this study at the ASH session entitled "Acute Myeloid Leukemia - Therapy, Excluding Transplantation".

In addition, PD data from the same study will be presented by Dr. Carter Bing of the MD Anderson Cancer Center in a poster on December 7 under the title "Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML".

Details of each of these presentations are listed below.

2008 ASH Annual Meeting ASH - Oral Presentation

Title: Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156)

in Co
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... England , May 24, 2013 ... Mundipharma angefertigt – Bei der ... , 91 % der Teilnehmer einer groß ... nur 20 % laut GINA [*] -Definition [1] ... dass Menschen mit Asthma generell einer von vier Denkweisen ...
(Date:5/23/2013)... ELMSFORD, N.Y. , May 23, 2013  BioScrip, ... the Company will present at the Jefferies 2013 Global ... the Grand Hyatt New York. ... and Hai Tran , Chief Financial ... 11:30 a.m. Eastern Daylight Time.   About ...
(Date:5/23/2013)... Patheon Inc ., a leading provider ... pharmaceutical industry, will host a complimentary webinar on “Cleaning ... Tuesday, June 4, 2013 at 11 a.m. Eastern Standard ... comply with regulations for cleaning validation. Many companies ... and little evaluation of risk. Some companies have ...
(Date:5/23/2013)... Francisco, CA (PRWEB) May 23, 2013 ... who encourage all types of inventions. They focus on ... now noticing this community gravitate toward bringing their ideas ... the DIY Biology Movement, works on making projects using ... the DNA of plants to make them glow with ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... may inadequately stimulate a patient,s heart while undergoing a ... pulses mixing with the electronic pulses from the pacemaker. ... patient undergoing the MRI scan, according to research published ... Online . MRI is an imaging technique that ...
... the Nanyang Technological University (NTU) signed the Memorandum of ... Research (CNRS) and the Thales Group of Companies to ... are meeting again in Singapore to inaugurate the CNRS-International-NTU-Thales ... at the Research Techno Plaza, the CINTRA Laboratory aims ...
... FREMONT, Calif., Dec. 16 WaferGen Biosystems, Inc. (OTC ... analysis systems, today announced that it will be launching ... gene-expression profiling using its SmartChip(TM) Real-Time PCR System. ... microRNA panel of 885 microRNAs on a single SmartChip. ...
Cached Biology Technology:FDA researchers identify new MRI safety risk for patients with pacemakers 2New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 4
(Date:5/23/2013)... cancer patients unnecessarily undergo surgery or harsh treatments ... slow-growing and aggressive forms of the disease. Researchers ... Medical Institutes are developing technology that allows patients ... relatively mild treatments or take drastic measures. , ... an associate professor of biomedical engineering at Case ...
(Date:5/23/2013)... in treating cerebral palsy with autologous cord blood. Following ... year old boy had been in a persistent vegetative ... months after treatment with the cord blood containing stem ... the child learned to speak simple sentences and to ... study, dispel the long-held doubts about the effectiveness of ...
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... Researchers at King,s College London have discovered how coral ... UV rays, leading scientists to believe these compounds could ... for humans. , The team has begun to uncover ... are produced and eventually hope to recreate them synthetically ...
... From medicine and food to energy and agriculture, ... to the challenges faced by societies in the 21st ... development of gluten-free wheat, could bring hope to those ... the world population nears seven billion people, biotechnology plays ...
... and the Child & Family Research Institute have shown that ... imprint on their sons, or daughters, genes an imprint ... are expressed later in life. The study, published online ... epigenetics the expression of genes as opposed to the ...
Cached Biology News:Tropical coral could be used to create novel sunscreens for human use, say scientists 2Tropical coral could be used to create novel sunscreens for human use, say scientists 3Parents' stress leaves lasting marks on children’s genes: UBC-CFRI research 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Biology Products: